Navigation Links
Advanced Life Sciences Ticker Symbol Reverts Back to 'ADLS.OB'
Date:4/27/2011

CHICAGO, April 27, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS.OB), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced that as of today the Company's ticker symbol has reverted back to "ADLS.OB."  Over the past 20 business days, the ticker symbol had a "D" temporarily appended to it indicating a recent reverse split.

(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired bacterial pneumonia (CABP) and biodefense pathogens including anthrax, plague and tularemia.  

For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers.  These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 /PRNewswire/ ... Research, titled, "Breast Imaging Technologies Market by Type: Global Opportunity ... imaging technologies market size was valued at $2,544 million in ... growing at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in ...
(Date:1/18/2017)... Jan. 18, 2017   Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative cell ... organs, recently reported the Company,s operating results for 2016 ... As the Company described in its recent 10-K ... of substantial accomplishments. The Company,s contract laboratory completed its ...
Breaking Medicine Technology:
(Date:1/19/2017)... Atlanta, Georgia (PRWEB) , ... January 19, 2017 ... ... Reconstructive Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of ... latest advancements in breast surgery. Covering topics from cosmetic breast augmentation ...
(Date:1/18/2017)... , ... January 18, 2017 , ... A recent video ... a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign raising ...
(Date:1/18/2017)... LAUDERDALE, FL (PRWEB) , ... January 18, 2017 ... ... how to manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. ... and often go untreated. , Certain Dri created this infographic to explain the ...
(Date:1/18/2017)... NJ (PRWEB) , ... January ... ... the specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists ... University Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian ...
(Date:1/18/2017)... ... 18, 2017 , ... PrideStaff, a national, franchised staffing ... Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with ... business leaders from across the globe, provides viewers an opportunity to find solutions ...
Breaking Medicine News(10 mins):